Company profile: Lytix Biopharma
1.1 - Company Overview
Company description
- Provider of anti-microbials and cancer therapeutics, developing LTX-315, an oncolytic peptide for the treatment of solid tumors, currently in Phase II clinical trials for basal cell carcinoma.
Products and services
- Cancer Therapeutics: Architects cancer therapeutics, oncolytic-peptide-enabled and targeting solid tumors, with applications evidenced by basal cell carcinoma development
- Anti-Microbials: Creates anti-microbial pharmaceuticals to address infectious threats, with a pharmaceutical-grade emphasis from a privately-owned specialist focused on anti-microbials
- LTX-315: Clinical-stage oncolytic peptide engineered for treating solid tumors, currently in Phase II clinical trials for basal cell carcinoma.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Lytix Biopharma
Aadi Bioscience
HQ: United States
Website
- Description: Provider of a potential mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aadi Bioscience company profile →
OnKure Therapeutics
HQ: United States
Website
- Description: Provider of next-generation oncology precision medicines targeting validated cancer drivers, developed by a clinical-stage biopharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full OnKure Therapeutics company profile →
Varian
HQ: United States
Website
- Description: Provider of medical devices and software for treating cancer and other conditions via radiotherapy, radiosurgery, proton therapy, and brachytherapy. Offers informatics software; products such as Ethos Adaptive Radiotherapy System, IntelliBlate Microwave Ablation System, Laguna Thrombectomy System, and Varian Marketplace, plus Advanced Oncology Solutions providing clinical and professional support and workflow solutions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Varian company profile →
Basilea
HQ: Switzerland
Website
- Description: Provider of innovative pharmaceutical products, including Cresemba, an intravenous and oral azole antifungal for invasive aspergillosis and mucormycosis, and Zevtera, an advanced-generation intravenous cephalosporin antibiotic for severe bacterial infections including Staphylococcus aureus bacteremia, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Basilea company profile →
Lengo Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical solutions focused on discovering and developing cancer treatments, including AYVAKIT/AYVAKYT (avapritinib) for systemic mastocytosis and gastrointestinal stromal tumors with PDGFRA exon 18 mutations. Offers clinical trials, a U.S. patient support program for access and affordability, and a scientific platform to develop highly selective medicines for mast cell disorders and cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lengo Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Lytix Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Lytix Biopharma
2.2 - Growth funds investing in similar companies to Lytix Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Lytix Biopharma
4.2 - Public trading comparable groups for Lytix Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →